Zacks Research upgraded shares of Kyntra Bio (NASDAQ:KYNB – Free Report) from a strong sell rating to a hold rating in a research note issued to investors on Tuesday,Zacks reports.
Other equities research analysts have also issued reports about the stock. Maxim Group began coverage on shares of Kyntra Bio in a research report on Tuesday, October 13th. They issued a “buy” rating and a $35.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $43.00 target price on shares of Kyntra Bio in a report on Tuesday, September 1st. Weiss Ratings downgraded shares of Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday. Finally, Lake Street Capital started coverage on shares of Kyntra Bio in a research report on Thursday, September 17th. They set a “buy” rating and a $41.00 target price for the company. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $36.80.
View Our Latest Report on Kyntra Bio
Kyntra Bio Stock Up 3.1%
Shares of KYNB stock opened at $3.68 on Tuesday. Kyntra Bio has a fifty-two week low of $3.50 and a fifty-two week high of $10.47. The stock has a market cap of $14.90 million, a P/E ratio of 0.08 and a beta of 1.08. The business has a fifty day simple moving average of $6.04 and a 200-day simple moving average of $6.92.
Hedge Funds Weigh In On Kyntra Bio
An institutional investor recently bought a new position in Kyntra Bio stock. Renaissance Technologies LLC acquired a new stake in Kyntra Bio Inc (NASDAQ:KYNB – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned approximately 0.68% of Kyntra Bio as of its most recent SEC filing. Hedge funds and other institutional investors own 72.71% of the company’s stock.
About Kyntra Bio
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Stories
- Five stocks we like better than Kyntra Bio
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.
